<code id='261C0FD4F9'></code><style id='261C0FD4F9'></style>
    • <acronym id='261C0FD4F9'></acronym>
      <center id='261C0FD4F9'><center id='261C0FD4F9'><tfoot id='261C0FD4F9'></tfoot></center><abbr id='261C0FD4F9'><dir id='261C0FD4F9'><tfoot id='261C0FD4F9'></tfoot><noframes id='261C0FD4F9'>

    • <optgroup id='261C0FD4F9'><strike id='261C0FD4F9'><sup id='261C0FD4F9'></sup></strike><code id='261C0FD4F9'></code></optgroup>
        1. <b id='261C0FD4F9'><label id='261C0FD4F9'><select id='261C0FD4F9'><dt id='261C0FD4F9'><span id='261C0FD4F9'></span></dt></select></label></b><u id='261C0FD4F9'></u>
          <i id='261C0FD4F9'><strike id='261C0FD4F9'><tt id='261C0FD4F9'><pre id='261C0FD4F9'></pre></tt></strike></i>

          
          WSS
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge